Compare Inovio Pharmaceuticals Inc (INO) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs MasTec Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while MasTec Inc trades at $212.74 (market cap $17.40B). The key difference: MasTec Inc is far larger — about 155.1× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and MasTec Inc for 23 Days on average.
| INO | MTZ | |
|---|---|---|
Market Cap | $112.19M | $17.40B |
Volume | 3,201,278 | 1,415,821 |
Sector | Health | Industrials |
52-Week High | $2.65 | $437.51 |
52-Week Low | $0.66 | $190.08 |
Typical Hold Time | 43 Days | 23 Days |
Enterprise Value | $83.51M | $20.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
MasTec (MTZ) trades at $214.84, down 3.82% on the day, with a bearish technical signal despite strong analyst support. The stock shows mixed earnings performance with recent beats but a Q2 2026 miss, while fundamentals reveal solid revenue growth and profitability metrics. The company benefits from record backlog and infrastructure demand, particularly in power delivery and data center markets.
MTZ presents a compelling long-term opportunity with 89% analyst buy ratings and a $408.58 consensus target, though premium valuation and weak cash flow pose risks. Infrastructure spending tailwinds and AI-driven demand support growth, but execution challenges and communications segment softness require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
